Michael R. Megna - Apr 4, 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Apr 4, 2024
Transactions value $
-$29,821
Form type
4
Date filed
4/8/2024, 05:18 PM
Previous filing
Apr 3, 2024
Next filing
Sep 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +3.93K +20.63% 23K Apr 8, 2024 Direct F1
transaction KNSA Class A Common Share Tax liability -$29.8K -1.67K -7.25% $17.90 21.3K Apr 8, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +18.9K $0.00 18.9K Apr 4, 2024 Class A Common Share 18.9K $18.06 Direct F2
transaction KNSA Restricted Share Unit Award $0 +9.45K +123.18% $0.00 17.1K Apr 4, 2024 Class A Common Share 9.45K Direct F1, F3
transaction KNSA Restricted Share Unit Options Exercise $0 -3.93K -22.96% $0.00 13.2K Apr 8, 2024 Class A Common Share 3.93K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.
F4 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.